ASMB Assembly Biosciences

Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020

Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020

SOUTH SAN FRANCISCO, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that it will hold its 2020 Annual Meeting of Stockholders (Annual Meeting) solely by means of remote communication (i.e., a virtual-only stockholder meeting). This change is to protect the safety, health and well-being of its stockholders, directors, employees and the public during the COVID-19 pandemic. As previously announced, the Annual Meeting will be held on Thursday, June 11, 2020 at 8:00 am PDT.

Stockholders will not be able to attend the Annual Meeting in person at a physical location. However, the virtual Annual Meeting will provide stockholders of record as of the close of business on April 13, 2020, the ability to participate, vote their shares and ask questions during the meeting via audio webcast.

Despite the change to a virtual-only meeting, the proxy card or voting instruction form, as applicable, included with previously-distributed proxy materials will not be updated to reflect the change from an in-person meeting to a virtual-only meeting and may be used to vote shares in connection with the Annual Meeting.

As provided in Assembly’s proxy materials, an online portal is available to stockholders at where stockholders can view and download the Company’s proxy materials and 2019 Annual Report and vote their shares in advance of the Annual Meeting. Stockholders may vote their shares during the Annual Meeting (up until the closing of the polls) by following the instructions available at during the meeting.

To be admitted to the virtual-only Annual Meeting, stockholders should visit and enter the 16-digit control number found on their Important Notice Regarding the Availability of Proxy Materials, their proxy card or the instructions that accompanied their proxy materials.

Below are additional details on how stockholders can participate in the virtual-only Annual Meeting:

  • Access the meeting platform beginning at 7:45 a.m. PDT on June 11, 2020.
  • Vote during the Annual Meeting by following the instructions available on the meeting website during the meeting.
  • Submit a question during the meeting by visiting   and entering the stockholder’s 16-digit control number and submitting the question in the “Ask a Question” field.
  • If any difficulties are encountered while accessing the virtual meeting, contact the technical support number that will be posted on the Virtual Shareholder Meeting log-in page. Technical support will be available beginning at 7:30 a.m. PDT on June 11, 2020 and will remain available until the meeting has ended.
  • A list of stockholders entitled to vote will be available for inspection by stockholders of record for any legally valid purpose related to the Annual Meeting during the Annual Meeting by following the link provided when stockholders login to and for a period of ten days prior to the Annual Meeting by sending a request to .

Whether or not stockholders plan to attend the virtual-only annual meeting, Assembly Biosciences urges stockholders to vote and submit their proxies in advance of the meeting by one of the methods described in the proxy materials.

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP manufacturing expertise and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit .

Contacts
Assembly Biosciences, Inc.
Amy Figueroa, CFA
Investor Relations Consultant
(415) 366-5158
  

Solebury Trout
Luke Brown
(646) 378-2944
 
EN
19/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Assembly Biosciences

 PRESS RELEASE

Assembly Biosciences Announces Pricing of $175 Million in Equity Finan...

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the “offering”) of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of ...

 PRESS RELEASE

Assembly Biosciences Reports Positive Interim Results from Phase 1b Cl...

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes – 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – – 94% reduction in genital lesion rate, also statistically significant, observed with 350 mg weekly oral dose compared to place...

 PRESS RELEASE

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study...

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus – Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Further pharmacological assessment to be conducted in parallel with Phase 2 preparation – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnol...

 PRESS RELEASE

Assembly Biosciences Reports Second Quarter 2025 Financial Results and...

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates – On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179 – – Positive topline data reported for Phase 1b study of ABI-4334, a next-generation highly potent capsid assembly modulator candidate, in participants with chronic hepatitis B virus (HBV) – – Interim data, including a biomarker for target engagement, reported from Phase 1a study in healt...

 PRESS RELEASE

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herp...

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop – Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates – – Preclinical data and U.S. genital herpes prevalence and treatment patterns also highlighted – – Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 – SOUTH SAN FRANCISCO, Calif...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch